Athol U Wells1,2. Show Affiliations » 1. Imperial College, London, UK. rbhild@rbht.nhs.uk. 2. Royal Brompton Hospital, London, UK. rbhild@rbht.nhs.uk.
Abstract
Entities: Disease
Mesh： See more » Antirheumatic Agents/therapeutic useAntirheumatic Agents/toxicityArthritis, Rheumatoid/complicationsArthritis, Rheumatoid/drug therapyConnective Tissue Diseases/complicationsConnective Tissue Diseases/drug therapyDisease ProgressionHumansIndoles/therapeutic useInterleukin-6/antagonists & inhibitorsLung Diseases, Interstitial/drug therapyLung Diseases, Interstitial/epidemiologyLung Diseases, Interstitial/mortalityLung Diseases, Interstitial/physiopathologyMethotrexate/therapeutic useMethotrexate/toxicityPrevalenceProtein Kinase Inhibitors/therapeutic usePulmonary Fibrosis/chemically inducedRandomized Controlled Trials as TopicScleroderma, Systemic/complicationsVital Capacity/drug effects
Substances： See more » Antirheumatic AgentsIndolesInterleukin-6Protein Kinase InhibitorsnintedanibMethotrexate
Year: 2021 PMID： 33408337 DOI： 10.1038/s41584-020-00567-x
Source DB: PubMed Journal: Nat Rev Rheumatol ISSN： 1759-4790 Impact factor: 20.543